Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? by Grootscholten, C. & Berden, J.H.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/51289
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Nephrol Dial Transplant (2006) 21: 1465–1469
doi:10.1093/ndt/gfl208
Discontinuation of immunosuppression in proliferative
lupus nephritis: is it possible?
Cecile Grootscholten and Jo H. M. Berden
Division of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Keywords: lupus nephritis; immunosuppression
withdrawal
Introduction
The search for an optimal therapy for proliferative
lupus nephritis (LN) is still ongoing [1,2]. Maintenance
treatment most often consists of low-dose prednisone,
generally combined with either azathioprine, hydroxy-
chloroquine or mycophenolate mofetil.
Since the prognosis of proliferative LN has improved
considerably and the morbidity of therapy is substan-
tial, the aim of treatment has changed from preventing
mortality to diminishing morbidity. Because of the
cumulative side effects of long-term immunosuppres-
sion, there is a constant effort to keep drug therapy at a
minimum and, wherever possible, to discontinue it
altogether. Compared with other manifestations of
systemic lupus erythematosus however, physicians may
be more reluctant to discontinue therapy in patients
with LN, especially since each ﬂare is considered a risk
factor for a worse renal outcome.
So far, no randomized controlled studies have been
carried out in which maintenance treatment after
reaching remission was withdrawn prospectively.
Relapses during immunosuppressive therapy
Exacerbations in proliferative LN are not uncommon.
Calculated renal relapse rates vary from 4 to 20 per
100 patient-years, depending on the aim of the study
and duration of follow-up [3–12]. In Figure 1, we have
depicted the renal relapse rate in patients with
proliferative LN. To correct for the different number
of patients and the duration of follow-up, we calculated
the ﬂare rate per 100 patient-years. Flare rates in three
categories of patients are given: during maintenance
therapy, during minimal immunosuppressive therapy
(only low dose steroids and/or hydroxychloroquine), or
after cessation of immunosuppression. These studies
cannot be compared with each other because of
differences in patient characteristics including ethnicity,
deﬁnitions of remission and relapse, time period and
previous and current treatment. Nevertheless, the ﬁgure
gives an impression of the observed relapse rates among
different groups of patients.
Clinically more meaningful is the cumulative inci-
dence of relapses. These data also vary greatly, from
27 to 66%. The observed relapse incidence depends
on several factors: (i) induction therapy: higher
incidence in patients treated with steroid monotherapy
compared with the treatment with a combination
of prednisone and cyclophosphamide; (ii) initial treat-
ment response: higher incidence after reaching
partial remission compared with complete remission;
(iii) demographic features: higher incidence in young
and/or black and/or male patients; (iv) histological
parameters: higher incidence with a higher activity
and/or chronicity index. For amore detailed description
of exacerbations of LN, we refer to a recent review
by Sidiropoulos et al. [13].
Relapses after minimization or discontinuation
of immunosuppressive therapy
Few studies have been published on the relapse
frequency in patients with proliferative LN after
minimization of immunosuppressive therapy or the
complete discontinuation of all drugs. Stopping cyclo-
phosphamide abruptly was associated with a rapid
deterioration of renal function [14] and therefore, seems
unwise.
In Table 1, we have summarized the studies in which
immunosuppression was either minimized (low-dose
corticosteroids and/or hydroxychloroquine) or stopped
completely. Most of these studies originate in Europe,
therefore these ﬁndings cannot be extrapolated to
patient groups with a different ethnic background.
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In 42 patients with proliferative LN who showed
improvement on induction therapy (either oral cyclo-
phosphamide with prednisone or prednisone alone)
and who were followed for a mean of 43 months,
Donadio et al. [15] observed a renal relapse rate of
8.6 per 100 patient years. Three of the 13 patients with
a ﬂare had discontinued prednisone, while the other
10 were still on maintenance therapy with low doses
of prednisone.
A Spanish retrospective study described 48 patients
with proliferative LN who reached remission after
treatment with cyclophosphamide (orally or intraven-
ously) and discontinued cyclophosphamide [16]. The
renal relapse rate was 8.3 per 100 patient-years
and the cumulative ﬂare incidence was 56% 10 years
after cyclophosphamide was stopped. However, no
information was given on maintenance treatment.
A higher renal relapse rate of 15.6 per 100 patient-
years was observed in 63 patients who had been treated
with cyclophosphamide pulse therapy for median
31 months and had reached partial or complete
remission [17]. Reaching partial remission as compared
with complete remission, the time to reach remission,
WHO-class IV and neurolupus at presentation were
predictors of renal ﬂare. In this cohort, maintenance
therapy was left to the decision of the treating physician.
A large study by the NIH showed renal relapses in
45% of the patients who had a partial or complete
response after induction therapy [18]. Patients had to
be off immunosuppressive therapy, with the exception
of hydroxychloroquine and low doses of prednisone.
The observed ﬂares were most often nephritic and were
associated with low C4 at the time of response and
African-American ethnicity.
There are only three research groups describing
LN disease course after the complete withdrawal of
immunosuppressive treatment. In a small group of
11 Spanish patients with proliferative LN, who had
been withdrawn from both immunosuppressive drugs
and corticosteroids for a minimum of 4 years, only
four relapsed [19]. The calculated renal relapse rate is
5.7 per 100 patient-years.
Two Italian groups have studied patients with LN
who discontinued all drugs. From 75 patients with
proliferative LN, treated with methylprednisolone and
pulse cyclophosphamide, 33 responded to treatment
and discontinued all drugs. Eighteen renal ﬂares
occurred in 15 patients. Eighteen patients did not
develop a ﬂare and remained off treatment [20]. The
same group describes that, after induction therapy but
without maintenance treatment, 54% of 91 patients
with proliferative LN developed a renal relapse, which
was then treated with either pulse steroids and pulse
cyclophosphamide or with high-dose corticosteroids
alone [21].
The calculated renal relapse rate in this extended
group is 15.6 per 100 patient-years. At the last
follow-up (median 72 months), 43% of the relapsing
patients showed a poor renal outcome (doubling of
serum creatinine or end-stage renal disease).
In this issue of Nephrology Dialysis and
Transplantation, Moroni et al. [22] report on a
cohort of 102 Italian patients with proliferative LN
in whom a trial was made to discontinue all immuno-
suppressive drugs after attaining remission. Only
44 (43%) were eligible. During reduction of immuno-
suppressive treatment, 12 out of 44 patients (27%)
developed a ﬂare (8 renal and 4 non-renal), while in the
remaining 32 patients, immunosuppression could be
stopped completely. In 17 of these, a relapse occurred
(53%): 13 patients had a renal and four had a non-renal
exacerbation.
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Fig. 1. Renal relapse rate (expressed in ﬂares per 100 patient-years; n/100py) in patients with proliferative lupus nephritis during, after
minimization or after discontinuation of immunosuppression (IS). Diamonds from top to bottom refer to the following references: during
maintenance IS: [5], [7], [9], [11], [3], [10], [4], [6] and [12]; during minimal maintenance IS: [17], [18], [15] and [16]; after discontinuation of IS:
[20], [19] and [22].
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Table 1. Renal relapse rate (expressed in ﬂares per 100 patient-years; n/100py) in patients with proliferative LN after minimization (low dose steroids and/or hydroxychloroquine) or after
discontinuation of immunosuppressive therapy
Author No. pat Country Time period FU (mean or median,
months)
Deﬁnition renal
relapse Screat
Uprot Uery/sediment Relapse rate
n/100py
Minimized maintenance therapy
Donadio et al. [15] 42 USA 1971–77 43 Renal function <75%* >3.0* or increase >2.0* NS 8.6
Ciruelo et al. [16] 48 Spain 1979–93 33 after CY discont. NS >0.5 or increase >1.0 >5/hpf with proteinuria
or active without Uprot
8.3
Ioannidis et al. [17] 63 Greece until 1999 ±28 after PR or CR >130%* >2.0* Active* 15.6
Illei et al. [18] 92 USA 1981–90 ±56 After CR 9.5
Proteinuric: ¼ Increase >2.0 Inactive
Nephritic:
mild ¼ Increase <2.0 >10 or casts
moderate ¼ Increase >2.0 >10 or casts
severe >130% >130% >10 or casts
After PR
Proteinuric: ¼ Increase >2.0 ¼
Nephritic:
mild <130% Increase <2.0 Increase
moderate <130% Increase >2.0 Increase
severe >130% >130% Increase
Discontinued therapy
Pablos et al. [19] 11 Spain 1971–91 77 after discont. NS >0.5 NS 5.7
Mosca et al. [20] 33 Italy 1976–98 48 after discont. >150% ** >1.0 ** >150%** 13.6
Moroni et al. [22] 32 Italy 1973–2004 203 after discont. Nephritic: >130% Increase Active 5.4
Proteinuric: ¼ 2 or increase >2.0 NS
No. pat¼number of patients with proliferative LN; FU¼ follow-up; Screat¼ serum creatinine; Uprot¼proteinuria (g/24 h); Uery¼ erythrocyturia; NS¼ not speciﬁed; discont.¼ discontinuation;
hpf¼ high-power ﬁeld; PR¼ partial remission; CR¼ complete remission.
*One of the criteria; **two or more criteria.
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Considering the original cohort of 44 patients,
complete withdrawal without disease ﬂare could be
attained in 15 patients (34%) and renal ﬂares occurred
in 21 patients (48%). At the last follow-up, 20 out of
44 patients (45%) were free of any immunosuppressive
drug. Beneﬁcial effects were shown by signiﬁcantly
lower cholesterol levels and a lower incidence of
osteoporosis.
When and how to withdraw immunosuppressives
It is difﬁcult, based on current available data,
to precisely deﬁne the criteria that allow the identiﬁca-
tion of patients in whom immunosuppression can
be stopped safely. A duration of therapy (including
induction) of at least 5 years seems warranted [22].
The disease should be quiescent, both clinically and
serologically. In patients who combine a number of
the described risk factors for renal ﬂares, one should
be reluctant to stop therapy completely. Based on the
observation that rapid tapering or abrupt cessation
of immunosuppression frequently leads to serious
relapses, the pace of dose reduction should be slow.
During this dose reduction, frequent monitoring seems
necessary, as proposed by Moroni and colleagues [22].
Besides renal parameters, this monitoring should
also include serological markers of disease activity
like anti-dsDNA titres and complement C3 and C4
measurements. Although their sensitivity and positive
predictive value for relapses differ greatly in the
literature [11,23], it is conceivable that in the absence
of immunosuppression, changes in these parameters are
more meaningful.
Conclusions and guidelines
Discontinuing maintenance therapy should only be
attempted in those (Caucasian?) patients with prolif-
erative LN who have been treated for at least 5 years
and who have had a long period of both clinically and
serologically quiescent disease, by slowly tapering the
drugs and under strict and frequent surveillance.
Because of the limited data available, it is difﬁcult
to predict the success rate, but discontinuation is
probably feasible in about one-third of the patients.
Although data are limited, a permanent decrease of
renal function may occur in another one-third of the
patients. These facts need to be taken into account
when counselling a patient on cessation of immuno-
suppressive therapy.
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The role of combination therapy in the management of hypertension
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The relationship of blood pressure
and cardiovascular risk
Data from the largest meta-analysis of hypertensive
patients clearly demonstrate that increasing systolic
blood pressure (BP) in any age group is associated with
very signiﬁcant increases in cardiovascular disease [1].
It has been shown that for every 20mmHg increase in
systolic BP, or for every 10mmHg increase in diastolic
BP, there is a doubling in the risk of cardiovascular
disease. Conversely, a meta-analysis of outcome studies
in the treatment of systolic hypertension demonstrated
that for every 20mmHg reduction in systolic BP there
is an 40–45% reduction in cardiovascular disease [2].
These studies have conﬁrmed the very signiﬁcant
cardiovascular risk associated with hypertension and
the impressive beneﬁts that can be derived from the
treatment of this disease process. Despite these
ﬁndings, worldwide epidemiological data have shown
that fewer than one-third of hypertensive patients
achieve a BP of <140/90mmHg [3].
The blood pressure values achieved
in clinical practice
Perhaps of even more concern is the fact that <50%
of treated hypertensive patients (patients on antihyper-
tensive medication and being followed by a physician)
have a BP of <140/90mmHg [4,5]. These are patients
who have been diagnosed and treated for hypertension
and for some reason inadequate BP control has been
accepted. There are now several studies that clearly
show that these patients remain at signiﬁcant risk for
cardiovascular disease. In the UKPDS study, two
groups of diabetic patients were differentiated; those
with ‘tight’ BP control and those with ‘less tight’ BP
control [6]. Since all patients in the study were being
treated with antihypertensive drugs, the comparison
was really one of treated hypertensive patients with
inadequate BP control compared with treated hyper-
tensive patients with what was considered by the
authors as adequate control. The difference in BP
between the two groups was only 10/5mmHg.
However, patients with tight control had 44% fewer
strokes and 21% fewer myocardial infarctions than
those with less tight control (Figure 1). Thus, more
aggressive treatment in patients already on antihyper-
tensive treatment, but with inadequate BP control,
has a signiﬁcant impact on the risk of cardiovascular
disease [6]. The HOT study was performed to assess
whether lower BP is better: each 5mmHg decrease in
diastolic BP resulted in further decreases in cardio-
vascular disease—again in a group of patients in
which everyone was being treated for hypertension
(Figure 2) [6]. In the diabetic cohort from the HOT
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